Technically Speakin...
Health Care: Drugs
Hemispherx Biopharma Inc. (HEB: AMEX)
$0.27 0.00 | 0.00%
06/04/12 - 01:03 PM ET
Company Cash Flow
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -9.02M | -13.14M | -13.44M | -12.22M |
| Operating Gains/Losses | 0.00 | 0.00 | -83.00K | 0.00 |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | 0.00 | 0.00 | 0.00 | 77.00K |
| (Increase) Decrease in Inventories | -110.00K | 77.00K | 0.00 | -288.00K |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | 424.00K | 362.00K | 1.88M | 1.70M |
| (Decrease) Increase In Other Current Liabilities | 201.00K | 123.00K | 45.00K | -120.00K |
| (Increase) Decrease In Other Working Capital | 6.00K | -7.00K | -5.00K | 450.00K |
| Other Non-Cash Items | -1.98M | -139.00K | 1.23M | 508.00K |
| Net Cash From Continuing Operations | -10.10M | -11.89M | -9.30M | -9.36M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -10.10M | -11.89M | -9.30M | -9.36M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 0.00 | 7.45M | 0.00 | 3.95M |
| Purchases of Property, Plant & Equipment | -2.04M | -1.07M | -574.00K | -215.00K |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | 0.00 | -49.89M | 0.00 | 0.00 |
| Other Cash from Investing Activities | -4.00K | -9.00K | 0.00 | 0.00 |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | 8.66M | -43.52M | -574.00K | 3.74M |
| Issuance of Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 0.00 | 293.00K | 61.82M | 270.00K |
| Repayment of Long-Term Debt | -71.00K | -43.00K | 0.00 | 0.00 |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 1.70M | 0.00 | 0.00 | 0.00 |
| Net Cash From Financing Activities | 1.62M | 250.00K | 61.82M | 270.00K |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | 183.00K | -55.15M | 51.95M | -5.35M |
Portfolios with HEB
- Portfolio NameUser Type
- Uservlady 1
- ContributorBarron's Insider Purchases ...
- ContributorBarron's Insider Purchases ...
- Usermaybe will work?
- UserTornado Portfolio
- Userjimb Portfolio 1
- Usergenomics
- User5for5
- Userjoe today
- UserNathan88
Latest HEB Headlines from TheStreet
- Hemisphrex Biopharma Announces Fiscal 2010 Year Results 03.29.11 | 01:03 pm
- Hemispherx Biopharma Reports On Annual Stockholder Meeting 03.22.11 | 02:03 pm
- Hemispherx Biopharma Announces 9th Clinical Investigators Conference: Ampligen Clinical Trials Highlighted 03.07.11 | 02:03 pm
- Chronix Biomedical And Hemispherx Biopharma Jointly File Patent Application For A Blood Test For Chronic Fatigue Syndrome (CFS) 03.03.11 | 10:03 am
- Hemispherx Biopharma Annual Meeting Set 02.24.11 | 08:02 am
- Hemispherx Biopharma, Inc. Announces It Has Scheduled Its 2010 Annual Stockholders' Meeting To Occur On March 17, 2011 In Remediation Of Notice From The NYSE Amex Of Non-Compliance With The Requirement To Hold Its Annual Stockholders' Meeting By The End Of 2010 02.23.11 | 01:02 pm
- Hemispherx Biopharma Appoints Senior Pharma Executive To Key Manufacturing Position 02.17.11 | 10:02 am
- Hemispherx Biopharma Announces US District Court Grants Final Approval Of Settlement Of Securities Class Actions 02.17.11 | 08:02 am
- FDA Authorizes Alferon LDO Clinical Study For Treatment And Prevention Of Influenza 01.04.11 | 10:01 am
- Hemispherx Biopharma, Inc. To Restate 2009 Financial Statements 12.28.10 | 04:12 pm
Press Releases for HEB
- Securities Class Action Filed By Shepherd, Finkelman, Miller & Shah, LLP On Behalf Of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 And November 2, 2009 - PR Newswire 12.08.09 | 04:12 pm
Partner Headlines for HEB
- Oink Oink: Profit From The Return Of Swine Flu - Benzinga 01.12.12 | 01:01 pm
- UPDATE 1-Hemispherx awarded $188 mln in "illegal" takeover suit - Reuters 08.18.10 | 12:08 pm
